ArticleBioscience reports2026
Modulating Galectin-1 in human osteoblast-like cells alters mineralisation and influences the expression of genes associated with osteoblasts and osteocytes.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genes Associated With Fracture Risk in Thoroughbred Horses Have Novel Roles in Osteogenesis.Animal genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bone formation, mineralisation, and remodelling are dependent on the activity of osteoblasts and osteoclasts. While many genes support bone development, their specific functions in the different stages of cell differentiation and maturation are often unknown. Galectin-1 (LGALS1) has roles in tumour angiogenesis and immune regulation but also enhances osteoblast differentiation of MSCs. The present study aimed to elucidate the role of LGALS1 in the osteogenesis of Saos2 cells. We demonstrated that Saos2 cells have a gene expression profile representing a mature osteoblast stage that shifts to an osteocyte-like profile under osteogenic conditions. We modulated LGALS1 using stable transfection to overexpress LGALS1 and lentiviral transduction of a short-hairpin RNA to knock down LGALS1. LGALS1 overexpression significantly reduced cell viability under basal culture conditions and significantly reduced mineralisation after 21 days of osteogenic culture. Knockdown of LGALS1 also significantly reduced cell viability under basal culture, but following osteogenic culture, a significant increase in mineralisation was observed. No effect on collagen deposition was seen following either knockdown or overexpression, suggesting that LGALS1 is involved in negatively regulating mineralisation. Osteogenic gene expression demonstrated few significant changes when LGALS1 was overexpressed. In contrast, knocking down LGALS1 resulted in many significant changes in osteogenic gene expression under both basal and osteogenic culture conditions. However, there was no clear correlation between the effect on gene expression and the increase in mineralisation. The present study demonstrated a novel role of LGALS1 in mature osteoblast-like cells. Further investigation into the regulatory pathways is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.